Abstract
<h3>To the Editor.—</h3> We were interested in the recent report of Nutt et al in theArchives(35:810-811, 1978) describing the failure of naltrexone to affect the conditions of patients with Parkinson's disease. We also found that naloxone hydrochloride, another potent opiate antagonist, has no obvious effect on the major manifestations of Parkinson's disease, on the therapeutic benefit of levodopa, or on levodopainduced dyskinesias. Four patients with idiopathic Parkinson's disease were given 0.8 mg of intravenous (IV) naloxone hydrochloride and a fifth patient was given 2 mg of IV naloxone hydrochloride. There was no subsequent change in tremor (evident in three patients), rigidity, akinesia, or posture. All patients had taken levodopa, usually with carbidopa (Sinemet), two to three hours earlier, but the manifestations of their Parkinson's disease were only partially reversed; there was neither an improvement nor a deterioration after administration of naloxone hydrochloride. Freezing episodes continued in two patients in
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
